Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

James Brumley, The Motley Fool

Sun, August 9, 2026 at 4:35 PM GMT+3 3 min read

• JNJ +0.99%
• NVDA -2.86%

It's certainly not the market's most exciting stock, and not its highest-yielding one either. If you want reliable dividend growth, though, you'd be hard-pressed to find a better option than drugmaker Johnson & Johnson (NYSE: JNJ).

In fact, after 64 straight years of annual dividend increases -- and counting -- only eight other Dividend Kings (companies that have raised their dividends for at least 50 consecutive years) can boast a longer streak of yearly dividend growth.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

This track record's likely to be extended indefinitely, too. Although drugs come and go with their patent protections and expirations, there are always new ways to reload a pharmaceutical company's pipeline and portfolio. Johnson & Johnson, for instance, is aiming for annual oncology drug sales of $50 billion by 2030, making it the biggest name in the cancer treatment business.

In other words, there's enough potential on the horizon for income-minded investors to consider a stake in J&J.

To this end, how much dividend income would a $10,000 position in the pharmaceutical powerhouse produce? That would mean around 39 shares at current prices. With a forward-looking dividend yield currently around 2.1%, this holding would generate close to $210 per year.

That's not a lot; you could certainly find higher-yielding dividend stocks to buy. It's not like Johnson & Johnson's recent dividend growth has been explosive either. It has only improved by 67% over the course of the past decade, for an average of about 5.3% per year. Not bad, but hardly thrilling.

Just bear in mind that J&J has become much more than a mere income investment since 2024, when it first made oncology a priority with a string of acquisitions like Shockwave Medical, Intra-Cellular Therapies, Halda Therapeutics, and, most recently, Firefly Bio. All of this dealmaking makes it a bit more of a growth investment. It's certainly been acting like one, gaining nearly 80% since the end of 2024.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,374,595!*

That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 9, 2026.

James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually. was originally published by The Motley Fool